Freya Rasschaert

Dr. Freya Rasschaert

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2019 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
SMSerge Masyn
Serge Masyn
AVAnneleen Vuchelen
Anneleen Vuchelen
ESEva Santermans
Eva Santermans
FRFreya Rasschaert
Freya Rasschaert
ABAllieu Bangura
Allieu Bangura
RRRomain Rutten
Romain Rutten
Biometric identification techniques for pediatric use are limited. This investigation studied iris scanning in minors aged 1–4 in two exploratory studies in Belgium (n = 197) and Sierra Leone (n = 230), and in a subsequent clinical study in Sierra Leone (n = 635). Images of participants’ irises were captured using a camera, while a survey assessed the ease of use with children. The image capture success rate per individual was high; 86.0% of the participants had ≥ 2 successful captures. Iris scan quality and surface were similar in all age groups and in the matching population database. When including feasibility in the analysis of minors aged 3–4, sensitivity and specificity were non-inferior compared to using the biometric of a guardian. However, the quality of iris scanning in minors aged 1–4 was worse than the iris scanning reference quality in adults. A mean total usability score of 1.55 ± 0.27 was calculated; a usability threshold of 1.45 is required for routine use. Overall, this technique is feasible in minors aged 3–4, replacing the use of guardian biometrics. Additional work is ongoing to improve this technique further, striving for uniformity from the age of 1.

12 July 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
ATAndrea Trujillo
Andrea Trujillo
LWLiesbeth Van Wesenbeeck
Liesbeth Van Wesenbeeck
LSLina Salazar
Lina Salazar
LLLiliana López
Liliana López
LTLotke Tambuyzer
Lotke Tambuyzer
FRFreya Rasschaert
Freya Rasschaert
Background: The evaluation of antiviral or vaccination strategies for the prevention of dengue infections in a traveler population would require extensive and complex studies. This prospective study aimed to identify a cohort of dengue naïve participants living in Medellín, a dengue endemic area, as a proxy for travelers and to determine the incidence of primary dengue virus (DENV) infection (symptomatic and asymptomatic) in this cohort. In Colombia, epidemic dengue waves occur every 3–4 years, with infected Aedes mosquitoes present in ~80% of the territory, including Medellín. Methods: Participants > 16 years of age, living in Medellín, were screened for anti-DENV immunoglobulin G (IgG). DENV seronegative participants were enrolled in this study. A serological anti-DENV survey was performed, with semiannual sample collections for up to 2 years. Acute DENV infections were evaluated by monitoring fever and testing for DENV nonstructural protein 1 and/or RNA. Results: Of the 4885 screened participants, 3008 participants (62%) were DENV seronegative and enrolled. Among them, 2263 (75%) completed this study, and 2644 (88%) had at least one serosurvey visit after baseline. Of those, 52 (2%) had laboratory-confirmed DENV seroconversion, and 19 (<1%) had febrile illness, but none had laboratory-confirmed DENV infection. Conclusions: This study identified a cohort of predominantly students, seronegative at study start, living in Medellín and serving as a proxy for a prospective DENV infection traveler population. Laboratory-confirmed primary DENV infection was found in 2% of participants, with <1% reporting febrile illnesses, meeting the WHO criteria for probable clinical dengue cases.

9 August 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
NGNele Goeyvaerts
Nele Goeyvaerts
XTXavier Woot de Trixhe
Xavier Woot de Trixhe
MNMartine Neyens
Martine Neyens
TKThomas N. Kakuda
Thomas N. Kakuda
LWLiesbeth Van Wesenbeeck
Liesbeth Van Wesenbeeck
OAOliver Ackaert
Oliver Ackaert
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM). A combined population pharmacokinetic (PopPK) and viral dynamic model (VDM) was developed to estimate the prophylactic effect of mosnodenvir and to inform dose selection. The PopPK model is a two‐compartment model based on plasma pharmacokinetic data from three Phase I studies and Cohort 1 of the Phase IIa study. Mosnodenvir exposure metrics were estimated for participants receiving high, medium, or low doses. A VDM with an immune response compartment adequately described DENV‐3 RNA profiles for placebo participants and was subsequently extended by including a sigmoid E max relationship with average mosnodenvir concentration at steady state ( C avg,ss ) to capture the antiviral effect on virion production rate. Simulations supported daily and weekly mosnodenvir dosing regimens to further characterize the pharmacokinetic/pharmacodynamic relationship in Cohort 2. Based on the complete Phase IIa study data, the basic reproductive number for DENV‐3 in this CHIM was estimated at 21.7, and the typical C avg,ss required to achieve complete virus eradication was estimated to be 1,410 ng/mL. In conclusion, the combined PopPK and VDM approach effectively informed dose selection and characterized the pharmacokinetic‐antiviral activity relationship, supporting the development of mosnodenvir as a prophylactic treatment for dengue infection.

17 June 2025 in Viruses
Verified
Journal Article
Open access
PDF file
EKErik Erik Koehne
Erik Erik Koehne
LWLiesbeth Van Wesenbeeck
Liesbeth Van Wesenbeeck
MHMartin Hibberd
Martin Hibberd
ABAnnemie Buelens
Annemie Buelens
MTMichiko Toizumi
Michiko Toizumi
LYLay Myint Yoshida
Lay Myint Yoshida
Background: Dengue is a global health concern, with half of the world’s population at risk and no antiviral treatment available. This Phase 0 study investigated dengue infections among household contacts (HHCs) of dengue index cases (ICs) and assessed the feasibility of conducting a Phase 2 trial for a novel antiviral. Methods: Participants were enrolled in Nha Trang, Vietnam, from April 2022 to February 2023. Dengue ICs were identified within 72 h of fever onset, and their healthy adult HHCs enrolled within 48 h. Blood samples and questionnaires were collected bi-weekly for four weeks, with a follow-up visit on day 40. DENV RT-qPCR, NS1, and anti-DENV IgM/IgG ELISAs were performed. Results: Overall, 130 dengue ICs and 301 HHCs were enrolled, with 91.7% (276/301) completing all follow-up visits. Baseline anti-DENV IgG showed prior dengue infections in 262/301 HHCs (87.0%). Fifty HHCs were excluded from the HHC infection analysis based on evidence of a DENV infection (viral load [VL], NS1, IgM, and IgG results) at enrollment. During follow-up, 2.0% of HHCs (5/251) had DENV infections based on virological parameters (DENV RNA and/or NS1 positivity), and anti-DENV IgG/IgM seroconversion was detected in 7.2% (18/251). Conclusions: This study demonstrated the operational feasibility of a dengue IC-HHC design for a Phase 2 trial.